title: [Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience].
abstract: Like interferon-alpha, interleukin 2 (IL2) is active on metastatic kidney cancers, which are regarded as chemoresistant tumors. Out of 20 to 30% objective responses, 5 to 10% complete remissions are reported with various IL2 delivery schedules. The considerable toxicity is well mastered at present, thus allowing treatment in non-intensive care departments, or even in an ambulatory mode for subcutaneous administration. Even though Interleukin 2 has been authorized for sale in France, optimal mode of administration, the role of the IL2-interferon-alpha combination or the predictive factors of response to treatment still raise many questions.
authors: Département de Médecine Carcinologique, Centre Léon Bérard, Lyon.
authors: S
authors: S
authors: Negrier
authors: A
authors: A
authors: Mercatello
authors: B
authors: B
authors: Coronel
authors: A
authors: A
authors: Ravaud
authors: Y
authors: Y
authors: Merrouche
authors: M
authors: M
authors: Bret
authors: F
authors: F
authors: Lanier
authors: J F
authors: JF
authors: Moskovtchenko
authors: T
authors: T
authors: Philip
mesh_terms: D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy*
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2
vernacular_title: Traitement par l'interleukine 2 du cancer du rein de l'adulte, l'expérience lyonnaise.